Halozyme Therapeutics Inc (HALO)

Add to Watchlists
Create an Alert
16.42 -0.09  -0.55% NASDAQ Sep 18, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
11/06/2019 16:30 EST Misc Halozyme Therapeutics Inc Third Quarter Earnings Conference Call in 2019
11/06/2019 Earnings Halozyme Therapeutics Inc Third Quarter Earnings in 2019 Release
08/06/2019 16:30 EDT Misc Halozyme Therapeutics Inc Second Quarter Earnings Conference Call in 2019
08/06/2019 Earnings Halozyme Therapeutics Inc Second Quarter Earnings in 2019 Release
05/07/2019 16:30 EDT Misc Halozyme Therapeutics Inc First Quarter Earnings Conference Call in 2019
05/07/2019 Earnings Halozyme Therapeutics Inc First Quarter Earnings in 2019 Release
05/02/2019 Misc Halozyme Therapeutics Inc Annual General Meeting in 2018
02/21/2019 16:30 EST Misc Halozyme Therapeutics Inc Fourth Quarter Earnings Conference Call in 2018
02/21/2019 Earnings Halozyme Therapeutics Inc Fourth Quarter Earnings in 2018 Release
02/21/2019 Misc Halozyme Therapeutics Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.halozyme.com
  • Investor Relations URL: http://www.halozyme.com/investors/default.aspx
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Nov. 06, 2019
  • Last Earnings Release: Aug. 06, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Top Fund Holders

Symbol Name Weighting
F000010YZ2 FT SMid Biotechnology Portfolio 3 F CA 2.77%
PBE Invesco Dynamic Biotech & Genome ETF 2.72%
PBE Invesco Dynamic Biotech & Genome ETF 2.72%
BBP Virtus LifeSci Biotech Products ETF 2.69%
BBP Virtus LifeSci Biotech Products ETF 2.69%
SBIO ALPS Medical Breakthroughs ETF 2.63%
SBIO ALPS Medical Breakthroughs ETF 2.63%
EAFRX First Eagle Fund of America R4 2.56%
HSCAX Hancock Horizon US Small Cap Inv 1.23%
HSCAX Hancock Horizon US Small Cap Inv 1.23%
GTSDX Invesco Small Cap Growth C 1.06%
FVUSA04AWV JNL/Invesco Small Cap Growth I 1.02%
QCSGX Federated MDT Small Cap Growth C 0.97%

Comparables

Edit

Excel Add-In Codes

  • Name: =YCI("HALO","name")
  • Description: =YCI("HALO","description")
  • Sector: =YCI("HALO","sector")
  • Industry: =YCI("HALO","industry")
  • Est. Current Fiscal Year End: =YCI("HALO","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.